Hologic, Inc. (NASDAQ:HOLX) Receives $84.62 Average Price Target from Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) have received a consensus rating of "Hold" from the seventeen ratings firms that are presently covering the firm, Marketbeat reports. Eleven equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $84.62.

Several research analysts recently commented on HOLX shares. Citigroup reduced their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. William Blair reissued an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Needham & Company LLC cut Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price for the company. in a research note on Monday, February 3rd. Leerink Partnrs lowered Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Finally, Morgan Stanley cut their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th.

Hedge Funds Weigh In On Hologic

A number of institutional investors have recently modified their holdings of HOLX. General Partner Inc. bought a new stake in Hologic during the fourth quarter valued at about $26,000. Venturi Wealth Management LLC grew its holdings in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the last quarter. Finally, Smithfield Trust Co grew its stake in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Remove Ads

Hologic Stock Performance

HOLX traded up $1.13 during midday trading on Tuesday, reaching $61.69. The company had a trading volume of 4,596,032 shares, compared to its average volume of 1,821,809. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic has a 1 year low of $58.38 and a 1 year high of $84.67. The business has a 50-day moving average of $64.69 and a two-hundred day moving average of $72.88. The company has a market cap of $13.84 billion, a P/E ratio of 19.46, a P/E/G ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts predict that Hologic will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.